A Phase 2/3 interventional study of Intravenous immunoglobulin and Trimethoprim / Sulfamethoxazole in Myeloma, Non-Hodgkin's Lymphoma and Leukemia, sponsored by Monash University. Recruiting at 3 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-07.
Sponsored by Monash University · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Neoplasms, Plasma Cell with a site in Australia — 6 open to participants now, 8 under way, 6 of them phase 3. Neoplasms, Plasma Cell · Australia.
Among the 22 studies in Neoplasms, Plasma Cell with a site in Australia, this one is the 3rd largest by planned enrollment of the 21 interventional ones that give a count, is one of 4 that started in 2025, is one of 5 in phase 2/3, and was the 19th registered.
710 studies on the registry are indexed under Neoplasms, Plasma Cell; 79 are open to participants now.
Browse Neoplasms, Plasma Cell studies →6 of the 22 studies in Neoplasms, Plasma Cell with a site in Australia are open now. Recruiting first, the newest first:
Monash University · Sites in Australia
Ages 18+
Monash University · Sites in Australia
Ages 18+
Monash University · Sites in Australia
Ages 18+
Pfizer · Sites in Australia, United States, Argentina and 24 more countries
Ages 18+
Monash University · Sites in Australia
Ages 18+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 58 Neoplasms, Plasma Cell studies recruiting now, 34 (59%) set no upper age limit and 12 (21%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 11 · Phase 3 11
First in 2005; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 900 is above the median of 40 across 527 interventional studies indexed under Neoplasms, Plasma Cell.
Median enrollment 187 across the 21 interventional studies. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 22 have an industry lead sponsor. The 10 most frequent:
Monash University is the lead sponsor of 83 studies on the registry; 22 are open to participants now.
Monash University has 5 studies filed under Neoplasms, Plasma Cell — fewer than ten, so there is no comparison to draw.
6 of the studies in Neoplasms, Plasma Cell with a site in Australia that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07202078Phase 3Monash UniversityRole of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig) | 2027-03-31 |
| NCT07202052Phase 3Monash UniversityRole of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) | 2027-03-31 |
| NCT07202091Phase 3Monash UniversityRole of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig) | 2027-03-31 |
| NCT07202065Phase 3Monash UniversityRole of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig) | 2027-03-31 |
| NCT05678621Phase 3Monash UniversityRole of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension | 2027-04 |
Add all 6 to your calendar (.ics) → With an account.
Among the 22 studies in Neoplasms, Plasma Cell with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an adaptive platform study to find out how safe and effective different strategies are in comparison to each other, for preventing infection in patients with blood cancers.
It is a comparison between Immunoglobulin and antibiotics use.
This study is being conducted to find out how safe and effective different strategies of infection prevention are in comparison to each other, for preventing infection in patients with blood cancers. The best way to find out this information is to directly compare the effect of different treatment strategies in patients with blood cancers. We want to know how these different treatments impact on your health and your use of healthcare services.
This research project uses an Adaptive Platform Design. This design allows the researchers to compare multiple infection prevention strategies within the same trial at the same time (rather than running separate trials), to analyse results as the trial occurs and to add new research questions during the course of the trial.
The treatments that you may receive as part of the study will be determined by which domain(s) of the platform you participate in. By combining data collected within each domain as part of the platform, the researchers can investigate and compare treatment strategies and infection outcomes across a broader range of participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1. Treating team deems enrolment in the study is not in the best interests of the patient.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients eligible to start immunoglobulin are randomly assigned to: * receive either prophylactic antibiotic * or Ig replacement.
Biological: Intravenous immunoglobulin · Drug: Trimethoprim / Sulfamethoxazole
Patients eligible to stop immunoglobulin are randomly assigned to: * Stop Ig and take daily antibiotics * Stop Ig and take antibiotics only when infections occur * Continue Ig therapy
Biological: Intravenous immunoglobulin · Drug: Trimethoprim / Sulfamethoxazole · Drug: Amoxicillin clavulanic acid
Patients receiving IVIg are randomly assigned to: * Continue with standard dose (0.4 g/kg) * Switch to a lower dose (0.25 g/kg)
Biological: Intravenous immunoglobulin (IVIG)
(IVIg) intravenous immunoglobulin every 4 weeks ± 1 week at a dose of 0.4g/kg, modified to achieve an (IgG) immunoglobulin G trough level of at least lower limit of age-specific serum IgG reference range; or SCIg, weekly, may be used in patients who meet local criteria for home-based self-administration in centres with established SCIg programs. Dosing is usually given at 100mg/kg/week, modified to achieve an IgG steady state level of at least the lower limit of the serum reference range. A loading IVIg dose may be given in the first month if required.
Also known as: Subcutaneous immunoglobulin
Once daily trimethoprim-sulfamethoxazole (co-trimoxazole) 160mg/800mg. Doxycycline 100mg daily as an alternative for patients with hypersensitivity to co-trimoxazole.
Also known as: co-trimoxazole
Patients will be provided with amoxycillin/clavulanic acid 1750-2000mg/250mg and ciprofloxacin 750 mg to keep at home for initial use if symptoms of infection develop, with immediate review by their treating clinical team, or nearest emergency department or medical practitioner with phone contact to treating team if most practical. Clindamycin 600 mg is permitted as an alternative to amoxycillin/clavulanic acid for patients with hypersensitivity to penicillin. Ciprofloxacin is omitted for participants with hypersensitivity.
Also known as: Ciprofloxacin
Arm A: Low dose (IgRT) immunoglobulin replacement therapy: Participants will be treated with intravenous immunoglobulin monthly (every 4 weeks ± 1 week) at a dose of 0.25g/kg. No dose adjustment for trough serum IgG levels is required. Arm B: Usual dose: Participants will be treated with intravenous immunoglobulin monthly (every 4 weeks ± 1 week) at a dose of 0.4g/kg, modified to achieve an IgG trough level of at least lower limit of age-specific serum IgG reference range.
Event-free survival (EFS)
Defined as time from randomisation (or, in domains with a single treatment arm, time from registration) until occurrence of a Grade 3 or higher infection (as defined by CTCAE Version 5), or death from any cause.
Time frame: 12 months following randomisation (or, in domains with a single treatment arm, time from registration)
Occurrence of at least one Grade 3 or higher infection(s) from randomisation to 12 months
Occurrence of at least one Grade 3 or higher infection(s) from randomisation to 12 months
Time frame: 12 months following randomisation (or, in domains with a single treatment arm, time from registration)
Occurrence of one or more clinically documented infections (symptoms/signs of infection requiring antimicrobial treatment) from randomisation to 12 months.
Occurrence of one or more clinically documented infections (symptoms/signs of infection requiring antimicrobial treatment) from randomisation to 12 months.
Time frame: 12 months following randomisation (or, in domains with a single treatment arm, time from registration)
Number of clinically documented infections (symptoms/signs of infection requiring antimicrobial treatment) from randomisation to 12 months.
Number of clinically documented infections (symptoms/signs of infection requiring antimicrobial treatment) from randomisation to 12 months.
Time frame: 12 months following randomisation (or, in domains with a single treatment arm, time from registration)
Occurrence of one or more microbiologically documented infections from randomisation to 12 months.
Occurrence of one or more microbiologically documented infections from randomisation to 12 months.
Time frame: 12 months following randomisation (or, in domains with a single treatment arm, time from registration)
Number of microbiologically documented infections from randomisation to 12 months.
Number of microbiologically documented infections from randomisation to 12 months.
Time frame: 12 months following randomisation (or, in domains with a single treatment arm, time from registration)
All-cause mortality at 12 months
All-cause mortality at 12 months
Time frame: 12 months following randomisation (or, in domains with a single treatment arm, time from registration)
Infection-related mortality at 12 months
Infection-related mortality at 12 months
Time frame: 12 months following randomisation (or, in domains with a single treatment arm, time from registration)
Time free from hospitalisation with antimicrobial administration with therapeutic intent from randomisation to 12 months.
Time free from hospitalisation with antimicrobial administration with therapeutic intent from randomisation to 12 months.
Time frame: 12 months following randomisation (or, in domains with a single treatment arm, time from registration)
Occurrence of one or more treatment-related adverse events
An adverse event includes any untoward medical occurrence that is not necessarily caused by the trial treatment. Examples of adverse events might include symptoms such as nausea, diarrhoea or headache. Adverse events will be collected via clinical examination, hospital medical record, or self-report to study team or via study diary. Adverse events will be graded using the Common Terminology Criteria for Adverse Events (CTCAE) Version 5. Relationship to treatment will be assessed by an Investigator at the trial site.
Time frame: 12 months following randomisation (or, in domains with a single treatment arm, time from registration)
Number of treatment-related adverse events.
An adverse event includes any untoward medical occurrence that is not necessarily caused by the trial treatment. Examples of adverse events might include symptoms such as nausea, diarrhoea or headache. Adverse events will be collected via clinical examination, hospital medical record, or self-report to study team or via study diary. Adverse events will be graded using the Common Terminology Criteria for Adverse Events (CTCAE) Version 5. Relationship to treatment will be assessed by an Investigator at the trial site.
Time frame: 12 months following randomisation (or, in domains with a single treatment arm, time from registration)
Isolation of fluoroquinolone resistant organisms, co-trimoxazole resistant organisms, extended spectrum beta lactamases or multidrug resistant organisms from randomisation to 12 months
Isolation of fluoroquinolone resistant organisms, co-trimoxazole resistant organisms, extended spectrum beta lactamases or multidrug resistant organisms from randomisation to 12 months
Time frame: 12 months following randomisation (or, in domains with a single treatment arm, time from registration)
Number of infections with fluoroquinolone resistant organisms, co-trimoxazole resistant organisms, extended spectrum beta lactamases or multidrug resistant organisms isolated from randomisation to 12 months
Number of infections with fluoroquinolone resistant organisms, co-trimoxazole resistant organisms, extended spectrum beta lactamases or multidrug resistant organisms isolated from randomisation to 12 months
Time frame: 12 months following randomisation (or, in domains with a single treatment arm, time from registration)
Quality of Life (QoL) measured at randomisation then 3, 6, 9 and 12 months, using the questionnaire.
Quality of Life (QoL) measured at randomisation then 3, 6, 9 and 12 months, using the questionnaire.
Time frame: Randomisation, Month 3, Month 6, Month 9 and Month 12
Costs associated with allocated treatment arm and infections during study.
Costs of infections and trial interventions will be estimated based on trial treatment and adverse event data within the hospital medical record, as well as linked data obtained from the Medicare Benefits Scheme (MBS), Pharmaceutical Benefits Scheme (PBS) and Australian Immunisation Register (AIR). Data from the quality of life questionnaires will be used to calculate quality adjusted life years.
Time frame: 12 months following randomisation (or, in domains with a single treatment arm, time from registration)
Plan to share: No — Individual participant data will not be publicly available. Data will only be presented as a whole, no individual data will be published or presented.
Started May 2025 (actual). Primary completion is estimated for Mar 2027, 22 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins, Intravenous
Monash University